Vaccinex
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1997-01-01
- Employees
- 40
- Market Cap
- $9M
- Website
- http://www.vaccinex.com
- Introduction
Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses on the development of Pepinemab for the treatment of non-small cell lung cance...
Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Vaccinex Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05102721
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Interventions
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Vaccinex Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT04815720
- Locations
- 🇺🇸
Messino Cancer Centers, Asheville, North Carolina, United States
🇺🇸Gabrail Cancer Research Center, Canton, Ohio, United States
🇺🇸Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)
- First Posted Date
- 2020-05-08
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Vaccinex Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT04381468
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇺🇸Indiana University School of Medicine, Indianapolis, Indiana, United States
🇺🇸JEM Research Institute, Lake Worth, Florida, United States
VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer
- First Posted Date
- 2017-08-31
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Vaccinex Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT03268057
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸University of California Los Angeles (UCLA), Los Angeles, California, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi
- First Posted Date
- 2015-06-25
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Vaccinex Inc.
- Target Recruit Count
- 301
- Registration Number
- NCT02481674
- Locations
- 🇺🇸
University of Vermont, Burlington, Vermont, United States
🇺🇸University of California, San Diego, La Jolla, California, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
- First Posted Date
- 2013-01-10
- Last Posted Date
- 2015-02-06
- Lead Sponsor
- Vaccinex Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT01764737
- Locations
- 🇺🇸
Wayne State University - University Health Center, Detroit, Michigan, United States
🇺🇸University of Colorado Hospital, Aschutz Inpatient Pavilion, Aurora, Colorado, United States
🇺🇸North Central Neurology Associates, PC, Cullman, Alabama, United States
Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors
- First Posted Date
- 2011-03-11
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Vaccinex Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT01313065
- Locations
- 🇺🇸
South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
🇺🇸Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, Arizona, United States